Silvestri F, Ermacora A, Sperotto A, Patriarca F, Zaja F, Damiani D, Fanin R, Baccarani M
Division of Haematology, Department of Bone Marrow Transplantation, University Hospital, Udine, Italy.
Br J Haematol. 2000 Feb;108(2):394-6. doi: 10.1046/j.1365-2141.2000.01847.x.
Reactivation of hepatitis B virus in patients receiving chemotherapy for non-Hodgkin's lymphoma (NHL) may give rise to hepatitis, hepatic failure and death, and prevent further chemotherapy. We report four patients with NHL in whom hepatitis flare-up was observed after two (three patients) and six (one patient) cycles of chemotherapy. After spontaneous recovery, they were treated with Lamivudine (100 mg/day), which enabled completion of chemotherapy without further hepatitis B reactivation. In one patient, high-dose chemotherapy and autologous stem cell transplantation was also performed. These data suggest a possible role for Lamivudine in preventing hepatitis B reactivation during chemotherapy administration to chronic carriers of the hepatitis B virus. Moreover, it enabled the completion of both standard and high-dose chemotherapy in patients with previous hepatitis B reactivation.
接受非霍奇金淋巴瘤（NHL）化疗的患者中，乙型肝炎病毒再激活可能导致肝炎、肝衰竭和死亡，并妨碍进一步化疗。我们报告了4例NHL患者，其中3例在化疗两个周期后、1例在化疗六个周期后出现肝炎发作。自发恢复后，他们接受了拉米夫定治疗（100毫克/天），从而能够完成化疗且未出现进一步的乙型肝炎再激活。其中1例患者还接受了大剂量化疗和自体干细胞移植。这些数据表明，拉米夫定在对慢性乙型肝炎病毒携带者进行化疗期间预防乙型肝炎再激活方面可能发挥作用。此外，它使既往有乙型肝炎再激活的患者能够完成标准剂量和大剂量化疗。
